11/26/2010 Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations Alsohaibani F, Peedikayil M, Alshahrani A, Somily A, Alsulaiman R, Azzam N, Almadi M, - Saudi J Gastroenterol
Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 741 

Previous Article  Table of Contents Next Article  
CLINICAL PRACTICE GUIDELINES  
Year :   |  Volume :   |  Issue :   |  Page :
Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations


1 Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia
2 Department of Medicine, Najran University, Najran, Kingdom of Saudi Arabia
3 Department of Pathology and Laboratory Medicine, King Saud University Medical City, Riyadh, Kingdom of Saudi Arabia
4 Department of Medicine, King Fahad Hospital, Imam Abdulrahman bin Faisal University, Dammam, Kingdom of Saudi Arabia
5 Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Kingdom of Saudi Arabia
6 Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Kingdom of Saudi Arabia; Division of Gastroenterology, McGill University Health Center, Montreal General Hospital, Montreal, QC, Canada

Click here for correspondence address and email
Date of Submission01-Jul-2022
Date of Acceptance19-Aug-2022
Date of Web Publication03-Oct-2022
 

   Abstract 


The eradication rates for Helicobacter pylori globally are decreasing with a dramatic increase in the prevalence of antibiotic resistant bacteria all over the world, including Saudi Arabia. There is no current consensus on the management of H. pylori in Saudi Arabia. The Saudi Gastroenterology Association developed these practice guidelines after reviewing the local and regional studies on the management of H. pylori. The aim was to establish recommendations to guide healthcare providers in managing H. pylori in Saudi Arabia. Experts in the areas of H. pylori management and microbiology were invited to write these guidelines. A literature search was performed, and all authors participated in writing and reviewing the guidelines. In addition, international guidelines and consensus reports were reviewed to bridge the gap in knowledge when local and regional data were unavailable. There is limited local data on treatment of H. pylori. The rate of clarithromycin and metronidazole resistance is high; therefore, standard triple therapy for 10–14 days is no longer recommended in the treatment of H. pylori unless antimicrobial susceptibility testing was performed. Based on the available data, bismuth quadruple therapy for 10–14 days is considered the best first-line and second-line therapy. Culture and antimicrobial susceptibility testing should be considered following two treatment failures. These recommendations are intended to provide the most relevant evidence-based guidelines for the management of H. pylori infection in Saudi Arabia. The working group recommends further studies to explore more therapeutic options to eradicate H. pylori.

Keywords: Bismuth, quadruple therapy, clarithromycin, Helicobacter pylori, metronidazole, Saudi Arabia, sequential, triple therapy


How to cite this URL:
Alsohaibani F, Peedikayil M, Alshahrani A, Somily A, Alsulaiman R, Azzam N, Almadi M. Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. Saudi J Gastroenterol [Epub ahead of print] [cited 2022 Dec 6]. Available from: https://www.saudijgastro.com/preprintarticle.asp?id=357812





   Epidemiology Top


Helicobacter pylori is one of the most prevalent infections worldwide. Although the prevalence of H. pylori is rapidly declining in developed countries because of improved sanitation and the widespread use of antibiotics, it remains high (>50%) in the majority of other countries.[1],[2] It is frequently acquired at an early age in developing countries compared with industrialized nations.[3] A recent systematic review and meta-analysis showed that North America had one of the lowest prevalence rates (37.1%), whereas Africa had the highest pooled prevalence (70.1%), followed by Latin America (63.4%) and Asia (54.7%).[4] Data from Saudi Arabia on prevalence of H. pylori were variable depending on geographical region, diagnostic methods, and period of study. The reported prevalence varied from 70% in 1989 to as low as 10.2% in 2018.[5],[6],[7],[8],[9],[10] The overall prevalence and time trends are difficult to ascertain due to the methods used in detection as well as heterogeneity in the population studied in Saudi Arabia. The published data on the prevalence of H. pylori in six different Saudi cities using different diagnostic methods is shown in [Table 1].
Table 1: Prevalence of Helicobacter pylori in Saudi Arabia

Click here to view


Transmission and risk factors

The risk of acquiring H. pylori infection is related to socioeconomic status and living conditions early in life. Factors such as density of housing, overcrowding, number of siblings, sharing a bed, and lack of running water have all been linked to a higher acquisition rates of H. pylori infection. The mode of transmission is still unclear, but evidence shows clusters in family members indicating the importance of fecal–oral or oral–oral exposure.[11] Humans are the major reservoir of infection; however, H. pylori has been isolated from milk and gastric juices of sheep.[12] Contaminated water supplies in developing countries may serve as an environmental source for bacteria in endemic areas.[13],[14] Isolation of H. pylori from the dental caries favor the risk of oral–oral exposure and transmission.[15]

Reinfection

The rate of reinfection in adults is uncommon and more likely related to recrudescence after partial suppression of H. pylori by antibiotics. In a large cohort from South Korea (10,468 eradicated subjects), reinfection of H. pylori was calculated to occur at the rate of 3.06% per person-year.[16] A prospective observational study performed in China including 3,728 patients with a median follow-up duration of 58.2 ± 13.6 months showed an annual reinfection rate of 1.5% per person-year. H. pylori reinfection was independently associated with ethnicity, lower education level, a family history of gastric cancer, and residence located in Western China.[17] Reinfection rates in Saudi Arabia have not been reported.

Diseases associated with H. pylori

H. pylori infection is responsible for a significant proportion of gastrointestinal morbidity worldwide, including acute and chronic gastritis, peptic ulcer disease (PUD), gastric adenocarcinoma, and gastric mucosal-associated lymphoid tissue (MALT) lymphoma.[18],[19] In 1994, H. pylori was classified as a definitive (Class 1) carcinogen by the World Health Organization because of its association with gastric cancer. A meta-analysis showed that the incidence of gastric cancer in individuals with eradication of H. pylori infection is lower than those who did not receive eradication therapy (pooled incidence rate ratio, 0.53; 95%(CI), 0.44–0.64).[20]

H. pylori and non-steroidal anti-inflammatory drugs (NSAIDs) act synergistically to increase the risk of ulcers and bleeding. Eradication of H. pylori before the start of chronic NSAID therapy reduces this risk.[21] H. pylori infection can also cause iron deficiency; therefore, eradication of H. pylori together with oral iron leads to significantly increased hemoglobin, iron, and ferritin levels compared with iron therapy alone.[22],[23] Idiopathic thrombocytopenic purpura (ITP) has been associated with H. pylori, and the American Society for Hematology recommends screening for H. pylori in adults with ITP and treating it in those found to be positive.[24],[25]




   Microbiology Top


Clinical isolates of H. pylori demonstrate genetic diversity depending on the geographic location which might explain the geographic variability in virulence and probably the incidence of gastric cancer. Each pathogenic virulence factor has stronger association with a certain clinical syndrome and an antimicrobial susceptibility pattern different from others.[26]

Specimen Collection and Transport

Culturing of gastric biopsy tissue allows for H. pylori identification, and antimicrobial susceptibility testing. However, the majority of H. pylori infection is diagnosed by non-cultural methods, such as rapid urease test (RUT), histopathology, urea breath test (UBT), stool antigen test (SAT), and serology.[27] The complex nature of the organism, growth requirements, and slow culture are major challenges during cultivating H. pylori. The sensitivity of culture in detecting H. pylori in infected biopsies is 50–70% even in expert laboratories.[28],[29],[30] Before the endoscopy, the patient should be off all antibiotics or bismuth substances for at least 4 weeks, and off proton pump inhibitors (PPIs) for at least 2 weeks. It is recommended to obtain biopsies from an inflamed or ulcerated area of the stomach, with two biopsies from the antrum and two biopsies from anterior and posterior corpus, in addition to samples from the antrum and corpus for histology and RUT.[31]

Appropriate collection, transportation, and storage of gastric biopsy specimens are crucial for efficacious culture of H. pylori. A transport media must be used to keep the organisms viable. Semisolid transport mediums can be used for prolonged transportation (more than 4 h), such as Stuart's transport medium, Portagerm (bioMerieux, Durham, N.C.), or  Brucella More Details broth with 20% glycerol.[32],[33],[34] For short transportation (less than 4 h) or when there is lack of transport media, saline with 20% glucose and glycerol act as a sufficient alternative.[35] The transported biopsy specimen requires to be maintained at a temperature less than 10°C for up to 16 h. If the culture of this specimen is not feasible to be performed within 24 h of collection, it is advised to freeze it at –70°C in dry ice, in a tube without medium, during transportation. It is recommended for long-term storage of H. pylori culture to use glycerol and maintain the culture at –70°C. Proper storage of biopsy specimen can allow 81% of recovery of H. pylori in the culture.[36]




   Diagnosis Top


Indications for testing

Tests for H. pylori should only be performed when eradication is planned if the test is positive. PUD is the primary indication; therefore, all patients with a new diagnosis or those who had a history of PUD and have not been tested should be tested for H. pylori infection.[37] MALT lymphoma is an important indication to test and eradicate H. pylori infection as the regression of low-grade gastric MALT lymphoma was reported in 60–93% of patients.[38] Treatment may also be beneficial for patients diagnosed with diffuse large B-cell lymphoma of the stomach.[39] In addition, patients with early gastric cancer or following gastric cancer resection and patients who are first-degree relatives of patients with gastric cancer are all indications to test and treat for H. pylori infection.

Dyspepsia in patients less than 60 years of age without alarm features should have non-endoscopic testing for H. pylori infections. For patients who have dyspepsia and undergo upper endoscopy because of age or presence of alarm symptoms, testing should be conducted on gastric biopsy tissue. Functional dyspepsia (FD) includes epigastric pain syndrome or post-prandial distress syndrome. Some FD patients with H. pylori infection experience improvement following eradication therapy; therefore, it is recommended to test and treat H. pylori in patients with FD. When performing endoscopy in patients with dyspeptic symptoms, it is recommended to biopsy the normal appearing gastric mucosa to test for H. pylori.[40]

Aspirin and NSAIDs are well-known risk factors for PUD and can be complicated by upper gastrointestinal bleeding. H. pylori increases the risk of bleeding from ulcers during their use and, therefore, it is suggested to consider to test and treat for H. pylori when starting low-dose aspirin (ASA) or in patients requiring long-term NSAID therapy.[37],[41],[42]

Iron deficiency anemia (IDA) has been associated with H. pylori infection. A meta-analysis conducted in patients with IDA and H. pylori infection found statistically significant differences in favor of H. pylori eradication in combination with oral iron over oral iron alone for increases in hemoglobin, serum iron, and serum ferritin levels.[43] In patients with ITP, there is evidence that showed improvement in platelet counts after eradication of H. pylori infection. In 2019, the American Society of Hematology recommended to test and eradicate H. pylori in ITP patients.[44] In Japan, platelet counts have been reported to increase in 40%–60% H. pylori-positive patients with ITP following H. pylori eradication; thus, eradication therapy should be one of the therapeutic interventions.[45] H. pylori has been associated with a number of other extra-gastroduodenal conditions; however, the causality of these associations is not proven [Table 2].
Table 2: Indications to consider testing and treating Helicobacter pylori infection

Click here to view


Population-wide screening and eradication of H. pylori to prevent gastric cancer in highly infected areas have recently been proposed by several consensus reports, including a recent Chinese consensus report[46] and Houston consensus conference.[47] A family-based prevention and eradication strategy has been proposed as a suitable approach to prevent intra-familial transmission and related diseases. Whether this approach is cost effective to extend testing and treating all family members, particularly those in close contact with H. pylori infected individuals, is unknown, particularly in areas with low incidence of gastric cancer such as Saudi Arabia.

Studies conducted in Japan have shown that H. pylori-positive patients with gastroesophageal reflux (GERD) have increased levels of gastric acid secretion and experience transient emergence or worsening of acid reflux symptoms or increased reflux esophagitis after H. pylori eradication.[48] However, other reports have documented that the incidence of erosive GERD does not increase after treating H. pylori in patients with peptic ulcers, and GERD symptoms can improve by eradication of H. pylori infection.[49] Therefore, Japanese guidelines for H. pylori management recommend eradication treatment for GERD patients.[45]


   Diagnostic Methods Top


Non-endoscopic tests

Tests for H. pylori infection can be done by non-invasive or invasive methods. Test-and-treat strategies involve non-invasive testing, followed by treatment in cases where tests are positive. Non-invasive tests include UBT, SAT, and serology.[50] Low bacterial load in the stomach because of gastrointestinal bleeding, atrophic gastritis, gastric MALT lymphoma, and gastric adenocarcinoma can lead to a decreased sensitivity of all diagnostic methods except serology. Serologic tests employ enzyme-linked immunosorbent assay (ELISA) to detect immunoglobulin IgG antibodies to H. pylori. There is significant variability in the accuracy of serology test for H. pylori, with sensitivity and specificity of 90–100% and 76–96%, respectively.[51],[52] Office-based kits that test whole blood can provide quick results and permit “point of care” testing. In most instances, serology remains positive for years after successful treatment of infection, this precludes the use of serology to confirm bacterial eradication after treatment.

UBT involves the ingestion of 13C or 14C-labeled urea. Hydrolysis of urea by bacterial urease generates ammonia and tagged CO2, which can be detected in breath samples.[53],[54] Patients should be fasting for at least 4 h before testing as this could increase the yield for diagnosis. UBT detects active infection and is useful for making the primary diagnosis and for documenting successful treatment with sensitivity and specificity of 88–96% and 93–100%, respectively.[55],[56] False-negative results have been reported in patients taking PPIs, bismuth, or antibiotics. To improve diagnostic accuracy, PPIs should be stopped at least 2 weeks before UBT, and bismuth and antibiotics should be stopped at least 4 weeks before UBT. SAT detects H. pylori antigens in stool with an ELISA test. It has good accuracy with a sensitivity and specificity of 95% and 97%, respectively.[57] The sensitivity of SAT is also reduced by recent PPIs, bismuth, and antibiotics use.

Endoscopic tests

Endoscopy is recommended in patients aged more than 60 years or in those with alarm symptoms and those with a family history of gastric cancer.[40] When endoscopy is indicated, there are three methods to identify the organism in a gastric biopsy specimen: RUT, histology, and culture. For RUT, gastric biopsy is tested for urease activity by placing the tissue in a medium containing urea and a pH reagent. Bacterial urease hydrolyzes urea, liberating ammonia, which produces an alkaline pH and a resultant color change of the test medium. RUT is efficient, easy, accurate, fast, and allows for immediate treatment with sensitivity and specificity values of 90–97% and 94–100%, respectively.[58] Accuracy is negatively affected by blood in the stomach or by recent use of certain medications, such as antibiotics, bismuth-containing compounds, or PPIs. Taking multiple biopsy samples from the antrum and corpus may be attempted to improve the diagnostic yield.[59]

Direct examination of biopsy

Histological examination is an excellent diagnostic test for H. pylori and considered to be the gold standard test. Detection of H. pylori is possible with standard hematoxylin and eosin (H and E) staining, but is significantly improved with increase in the number of slides examined and special stains such as Giemsa, silver, Genta, or specific immune stains with reported sensitivity and specificity as high as 95% and 98%, respectively.[60],[61],[62] The use of immunohistochemistry may shorten the time required for the detection of bacteria in cases with a low level of organisms, with a sensitivity and specificity of 97–98% and 90–100%, when compared to Genta and H and E stains, respectively.[63],[64] Histological examination of biopsy samples enables accurate detection of the bacterium, the assessment of inflammation and detecting gastritis, intestinal metaplasia, dysplasia, or malignancy. Histological sampling for H. pylori diagnosis should include an antrum and a corpus biopsy to account for the distribution of H. pylori.[65],[66],[67] Biopsies could be taken according to the Sydney protocol, which includes five biopsies encompassing the lesser curvature of the antrum within 2–3 cm of the pylorus, the greater curvature of the antrum within 2–3 cm of the pylorus, the lesser curvature of the body 8 cm distal to the cardia, the greater curvature of the body 8 cm distal to the cardia, and the incisura angularis.[68]

H. pylori culture and antibiotic susceptibility testing

H. pylori is difficult to culture because the organism is fastidious, slow growing (10–12 days), and requires specialized media and growth environment. The culture is highly specific with positivity rates ranging between 50% and 93%.[30],[69] H. pylori culture with antibiotic sensitivity testing is recommended in patients with refractory infection to guide subsequent treatment; however, in vitro sensitivity testing does not always predict clinical treatment response.[70],[71],[72] Because of the rising incidence of antimicrobial resistance worldwide, it is recommended whenever possible to consider culture and antimicrobial susceptibility testing, particularly in regions with well-documented high antimicrobial resistance or after a failure of two regimens to tailor the treatment. Several studies using tailored treatments based on H. pylori susceptibility to antibiotics in comparison with standard empirical triple therapy have shown a better eradication rate and might be cost- effective.[50]

The rate of resistance varies from one country to another, a recent review showed a rate of resistance of about 10–30% to clarithromycin and levofloxacin and high resistance rate to metronidazole 23–56%.[73] In Saudi Arabia, a prospective study reported that H. pylori resistance was 48.5% for metronidazole, 23.3% for clarithromycin, 14.8% for amoxicillin, 11.1% for levofloxacin, and 2.3% for tetracycline.[74] Direct measurements with the agar dilution method is the gold standard for antibiotic susceptibility testing for H. pylori; however, it requires laborious preparation and may not be cost- or time-effective for daily clinical practice. E-test uses different concentrations of antibiotics in a single strip as an alternative and maybe preferable in clinical practice because of the lower cost and for being less time-consuming.[75]

Polymerase chain reaction (PCR) assays are a rapid and highly sensitive and specific method for the laboratory diagnosis of H. pylori infection in gastric biopsies or stool. It is a sensitive method to detect H. pylori, and has gained in popularity lately. It allows detection of 23S rRNA, gyrA, rdxA, pbp1, 16S rRNA, and rpoB gene mutations associated with clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin resistance, respectively. It is also useful for research purposes or to examine drinking water in a community setting, to type organisms in epidemiologic or transmission studies, and for “real-time” antibiotic resistance testing[76] [Table 3] and [Table 4].
Table 3: Available PCR tests to detect Helicobacter pylori in gastric biopsies

Click here to view
Table 4: Endoscopic and non-endoscopic diagnostic tests

Click here to view


Post eradication testing

Resolution of symptoms is not an accurate indicator of treatment success; therefore, all individuals treated for H. pylori should be offered a test to confirm successful eradication, in particular those with PUD, MALT lymphoma, early gastric cancer, and dyspepsia. False negative results for post eradication testing are usually associated with taking PPIs and antibiotics through inhibiting growth and by their bactericidal activity against H. pylori.[77],[78] For this reason, eradication testing should be done at least 4 weeks following completion of antibiotics and at least 2 weeks following stoppage of PPI therapy.[79] UBT is the best option for H. pylori eradication test.[80] SAT is less accurate but can be used as an alternative.[81] Serology testing is not recommended for eradication confirmation as antibodies persist for months following clearance of infection. When endoscopy is performed, a biopsy from the antrum and the corpus should be taken for RUT that has a sensitivity and specificity for H. pylori detection post eradication of 44–88% and 98–100%, respectively.[82]





Factors affecting cure from H. pylori are the duration of treatment, compliance to treatment, high gastric acidity, high bacterial load, bacterial strains, and antimicrobial resistance.[50] However, knowledge on the geographical prevalence of H. pylori resistance to antimicrobials influences treatment regimens the most. For the successful eradication of H. pylori infection, a combination of effective antibiotics should be selected based on antibiotic resistance prevalence, given for an adequate duration; in addition, compliance to the given treatment and adequate acid suppression is essential.[37] The goal of H. pylori therapy is to achieve eradication in ≥90% of treated patients by initially using the most efficacious therapies available. The therapeutic options depend on their availability, cost, convenience, resistance pattern, and presence of allergies.

Prevalence of antibiotic resistance of H. pylori strains in Saudi Arabia

H. pylori resistance to clarithromycin in Saudi Arabia ranges from 8.8% to 39.9%, fluoroquinolone resistance between 8.4% and 11.1%, and metronidazole between 48.5% and 80%. Resistance to amoxicillin and tetracycline was reported to be 14.6–14.8% and 2.3–9.5%, respectively.[74],[83],[84],[85] When the prevalence of clarithromycin resistance in a geographical area is >15%, treatment regimens containing clarithromycin become less effective. Similarly, when fluoroquinolone resistance is high, the eradication with levofloxacin-based triple therapies reduces. Similarly, the eradication rates using metronidazole-based triple therapy diminishes significantly in areas where metronidazole resistance is high [Figure 1].
Figure 1: Rate of Helicobacter pylori antibiotic resistance in Saudi Arabia

Click here to view


Treatment regimens available for H. pylori

When treating H. pylori, all efforts should be made to achieve eradication rates of ≥90%, keeping in consideration that failing to cure the infection from the first line of treatment might reduce the cure rate in subsequent therapies. Therefore, the most effective available regimen should be used first. The regimens with dosages, durations, and eradication rates are shown in [Table 5].
Table 5: Treatment regimens and mean pooled eradication rates from different meta-analysis

Click here to view


Triple therapy

Triple therapy consists of a combination of two antibiotics: amoxicillin, clarithromycin or metronidazole, and PPI. This combination is given from 7 to 14 days. The overall efficacy of standard triple therapy, including PPI, amoxicillin, and clarithromycin (PAC), in comparison with other treatment regimens was 60–82% on an intention-to-treat (ITT) analysis basis.[86],[87],[88],[89],[90],[91],[92],[93],[94],[95] In most countries, standard triple therapy has a below therapeutic eradication rate.[96] Antibiotic resistance causes a decrease in the eradication rate of H. pylori.[97] In geographical areas where clarithromycin resistance is more than 15%, the eradication from clarithromycin-based triple therapies is generally suboptimum.[96] Seven days of triple therapy should be avoided because of very low eradication.[98] Longer duration (14 days) was associated with a higher eradication rate, but with a higher risk of events that lead to discontinuation.[96]

The data from Saudi Arabia show that the eradication rate of H. pylori with a combination of PAC for 14 days was 59% in ITT analysis, and in per-protocol analysis, the eradication was 67.6%. Clarithromycin resistance in this study was 23.3%.[74] Because of the very low eradication rate with standard triple therapy, alternative regimens should be tried as first-line treatment in Saudi Arabia. Different guidelines recommend or suggest clarithromycin or metronidazole-based triple therapies for 14 days only in geographical areas where this treatment has proven satisfactory efficacy and/or with low clarithromycin resistance for clarithromycin-based therapy and low metronidazole resistance for metronidazole-based triple therapy.[37],[83] Meta-analyses comparing PPI, amoxicillin, and metronidazole (PAM) versus clarithromycin including triple therapies (PAC/PMC) showed total cure rates of all triple therapies as less than 90%, with a significant difference in favor of PAC (70% vs. 77.1%; OR = 0.70, 95% CI = 0.56–0.88) and PMC therapy (66.4% vs. 77.7%; OR = 0.55, 95% CI = 0.39–0.76). Sensitivity analyses showed a similar efficacy of PAM versus PAC when drugs were administered for 14 days (80% vs. 84%; OR = 0.70, 95% CI = 0.44–1.12). Number of antibiotic doses (P = 0.012), length of treatment (P < 0.001), and use of high metronidazole doses ≥1.5 g/day (P = 0.021) were associated with higher eradication rates. Giving antibiotics every 8 h instead of every 12 h increases eradication rates.[99]

Bismuth-containing quadruple therapy

Quadruple therapies (bismuth based and non-bismuth based) for 10–14 days are able to achieve ≥ 90% eradication rates. For the first-line treatment of H. pylori, 10–14 days course of bismuth-containing quadruple therapy has an overall eradication rate of 77.6–90% by ITT analysis.[88],[93],[94],[95] In a meta-analysis, the efficacy of a 10-day course of single-capsule bismuth quadruple therapy (Pylera®) was 90% on ITT analysis as first-line therapy, 89% as a second-line treatment, and 82% as a third-line treatment. This treatment response was regardless of the type and dose of the PPI, including for patients with clarithromycin or metronidazole-resistant strains, and in those previously treated with clarithromycin.[94] In another meta-analysis, bismuth quadruple therapy and concomitant therapy were found good treatment options for H. pylori infection. However, bismuth quadruple therapy was superior to the current scheme of concomitant therapy in a subgroup analysis.[95] In a multicenter, prospective registry, Pylera® had a modified ITT effectiveness of 92%, eradication was more than 90% in first-line treatment, and was maintained as a rescue therapy as both second (89%) and subsequent lines of therapy (92%).[100]

A study from Saudi Arabia found an eradication rate of 78.3% (ITT analysis) using Pylera® with PPI for 10 days and 87.8% in a per-protocol analysis; and previous treatment failure did not affect the treatment response.[101] This is higher than the treatment response obtained from standard triple therapy in Saudi Arabia.[74] It has been also reported that adding probiotics to bismuth-based quadruple therapy may improve the eradication rate of H. pylori, especially in patients receiving front-line eradication regimens or in patients who have had a failed triple therapy. Probiotics may reduce the adverse reactions when combined with other eradication agents.[102] We also recommend further studies to clarify if a 10-day course of quadruple therapy is as effective as a 14-day regimen.

Non-Bismuth-based quadruple (concomitant) therapy

In concomitant therapy, three antibiotics and a PPI are given in two divided doses for 10–14 days. In an open-label, randomized clinical trial, eradication rates for the concomitant group compared to the hybrid therapy group were 84.1% on ITT and 96.7% on per-protocol analysis.[103] In a meta-analysis, the efficacy of concomitant therapy was found to be duration dependent. In comparison with sequential therapy, a 10-day concomitant therapy was superior. Another observation was that when compared to sequential therapy, concomitant therapy was more efficacious for metronidazole-resistant strains, and metronidazole plus for clarithromycin-resistant strains. However, diarrhea was more frequent with concomitant therapy than with sequential therapy.[104]

Sequential therapy

In sequential therapy, in the first 5 days, one antibiotic and a PPI are given twice daily for 5–7 days; then, clarithromycin, metronidazole or tinidazole, and a PPI are given twice daily for the next 5–7 days. The treatment response to sequential therapy is generally influenced by the prevalence of resistance to clarithromycin and metronidazole. In areas with high resistance to clarithromycin, sequential therapy was superior to 14-day triple therapy. In areas with high metronidazole resistance, sequential therapy and 14-day triple therapy were equivalent. Overall, sequential therapy for 10 or 14 days was not significantly superior to 14-day triple therapy. However, 14-day sequential therapy was significantly more effective than 14-day triple therapy as first-line treatment.[105]

In a meta-analysis, sequential therapy was more effective than triple therapy, especially when sequential therapy was given for only 7 days. Nevertheless, the apparent advantage of sequential therapy has decreased over time, and more recent studies do not show sequential therapy to have a higher efficacy versus triple therapy when triple therapy is given for 10 days. Although sequential therapy offers an advantage when compared with triple therapy, it cannot be presented as a valid alternative, given that neither regimens achieved optimal efficacy (≥90% eradication rate).[106] The overall mean pooled eradication rate was 82% from different meta-analyses.[90],[107],[108] Sequential therapy has been tested in clinical trials from Saudi Arabia for first-line treatment of H. pylori and as second-line treatment in Egypt.[74],[109] A randomized controlled trial has shown eradication rate from 10-days sequential therapy was 62.3% (ITT analysis). In addition, there was no statistical difference between sequential therapy and triple therapy. The treatment response was better with triple therapy (67.6%) than with sequential therapy.[74] In Korea, quinolone-containing sequential therapy for 14 days was found to be better than standard sequential therapy with a 91.4% eradication rate in the ITT analysis.[110]

Hybrid therapy

In hybrid therapy, we use PPI and amoxicillin for 7 days, followed by PPI, amoxicillin, clarithromycin, and metronidazole for 7 days. In a randomized study, the hybrid scheme resulted in an 85% eradication rate on ITT analysis and 91% as per protocol, and it was found to be significantly more effective than standard triple therapy.[111] From the meta-analysis, compared with sequential therapy or concomitant therapy, hybrid therapy gave a similar yield of eradication, high compliance rate, and acceptable safety profiles.[112] From a clinical trial from Taiwan, 96.4% eradication rate was achieved from the hybrid therapy on per protocol analysis compared to 81.9% with sequential therapy. It appeared that hybrid therapy was an appropriate eradication regimen in Taiwan.[113] There are no studies available from Saudi Arabia on hybrid therapy.

High-dose dual therapy

In high-dose dual therapy, a PPI and amoxicillin are given three times a day for 14 days or four times a day for 10 days.[114] In a network meta-analysis that compared sequential therapy, bismuth-based quadruple therapy, concomitant therapy, and hybrid therapy, high-dose dual therapy for 14 days appeared to be the most optimal first-line therapy for H. pylori among Asian populations, with comparable efficacy and compliance and with fewer adverse events. Pooled efficacy of high-dose dual therapy was found to be 83.2% versus 85.3% on ITT when it was compared with other guidelines-recommended therapies.[115] There is no data from Saudi Arabia on high-dose dual therapy.

Levofloxacin-based regimens

The cumulative eradication rate of levofloxacin triple therapy in a systematic review was 80.7% (95%CI: 77.1–83.7) as first-line treatment and 74.5% (95%CI: 70.9–77.8) as second-line treatment. The efficacy of levofloxacin triple therapy before 2008 was 77.4% and after 2012 was 74.8%. The eradication rate was higher when levofloxacin was given once daily (80.6%, 95%CI: 77.1–83.7) than when given twice daily (73.6%, 95%CI: 69.7–77.2). The efficacy was significantly higher in levofloxacin-susceptible strains than in resistant strains (81.1% vs. 36.3%, risk ratio 2.18, 95%CI: 1.6–3, P < 0.001).[116]

Another meta-analysis showed that 7 days of levofloxacin triple therapy was found to be equal to 7 days of triple therapy as first line treatment. The crude eradication rate in the levofloxacin group was 79.05% versus 81.4% in the standard group (risk ratio 0.97; 95%CI: 0.93, 1.02).[117] There is no data available from Saudi Arabia exploring the role of levofloxacin-based triple therapies or sequential therapies as a first-line treatment for H. pylori. However, as rescue therapy, levofloxacin-based triple therapy was found to be suboptimum in Saudi Arabia. In a trial conducted by Alsohaibani et al.,[118] 55 patients who failed to respond to different kinds of H. pylori treatments were given levofloxacin, doxycycline, and esomeprazole for 10 days. H. pylori eradication was achieved in 20 out of 51 patients (39.22% per protocol analysis and 36.36% by ITT analysis). Therapy was well tolerated, and side effects were generally mild.

Moxifloxacin-based sequential therapy

In a study from South Korea, moxifloxacin-based sequential therapy (MBST) was found to be better than hybrid therapy; both treatments were given for 14 days. The eradication rates in the ITT analysis were 91.4% (128/140; 95%CI: 90.2–92.9%) in the MBST group and 79.2% (114/144; 95%CI: 77.3–80.7%) in the hybrid group (P = 0.013).[119] Pooled H. pylori eradication rates for first-line or second-line treatments were 79.03% (95%CI: 75.73–82.07) and 68.33% (95%CI: 64.44–72.04) for patients with moxifloxacin-based triple therapy or with standard triple or quadruple therapy, respectively, by ITT analysis.[87]

Rifabutin triple therapy

There is no data available on the efficacy of rifabutin-based therapy from the Middle East. The overall efficacy of rifabutin-containing regimens in Europe was 78%, 80%, and 66% by modified ITT as second-, third-, and fourth-line regimens, respectively.[120] In a meta-analysis, only one randomized controlled trial had compared rifabutin therapy with control as first-line treatment (OR 3.78, 95%CI: 2.44–5.87, P < 0.0001). It was found that the treatment was more likely to be successful in Asian versus non-Asian populations (81.0% vs. 72.4%, P = 0.001), and when daily amoxicillin dose was ≥3,000 mg or PPI dose was ≥80 mg or treatment duration was 14 days (80.6% vs. 66.0%, P = 0.0001).[121] As second line therapy, 7-day rifabutin and amoxicillin regimen was compared to 7-day bismuth-based quadruple therapy. In a randomized trial, eradication achieved in an ITT analysis was 44.4% and 70.4% for rifabutin and bismuth-based quadruple therapy, respectively, (OR = 1.58, P = 0.009).[122]

PPI in the treatment regimens

Esomeprazole was found to be the most effective PPI, followed by rabeprazole, while no difference was observed among the three older generations of PPI for the eradication of H. pylori.[123] In one study, distribution of CYP2C19 phenotypes with extensive metabolizers was found to be 77.6% in Saudi Arabia.[124] This may affect the adequacy of acid suppression with conventional PPI. A clinical trial using potent acid suppressors other than a PPI, such as vonoprazan, would be of interest.

The role of vonoprazan-based treatments instead of PPI

The efficacy of vonoprazan (a potassium-competitive acid blocker) based triple therapy was found to be superior to that of PPI-based triple therapy for first-line H. pylori eradication. Additionally, vonoprazan-based triple therapy is better tolerated than PPI-based triple therapy.[125] Eradication rate was 77.5% in the esomeprazole group, 68.4% in the rabeprazole group, and 90.8% with vonoprazan.[126] A vonoprazan-based regimen has significant superiority over a PPI-based regimen for second-line H. pylori eradication therapy. Avonoprazan-based second-line H. pylori eradication regimen can be the first choice.[127] Almost all studies related to vonoprazan have been conducted in Japan. There are no data available from Saudi Arabia for vonoprazan as an acid suppression agent.

Which treatment regimens are appropriate to treat H. pylori in Saudi Arabia?

In Saudi Arabia, the available data from prospective studies suggest that triple therapy and sequential therapy are suboptimal for the treatment of H. pylori while bismuth-based quadruple therapy (Pylera®) is superior as first-line treatment.[74],[101] Until now, there are no clinical trials available from Saudi Arabia to assess the efficacy of concomitant therapy, hybrid therapy, and high-dose dual therapy; hence, clinical trials should be conducted to clarify their role. Until then, bismuth-based quadruple therapy (including Pylera®) should be considered as a first- and second-line treatment for H. pylori [Figure 2], [Figure 3], [Figure 4] and [Table 6].
Figure 2: Selection of first-line Helicobacter pylori treatment regimen as recommended by American College of Gastroenterology (ACG). [37]*In regions where clarithromycin resistance is known to be >15%, use recommendations for patients with a history of macrolide exposure. **Levofloxacin, omeprazole, nitazoxanide, and doxycycline

Click here to view
Figure 3: Eradication rates of Helicobacter pylori from Saudi Arabia as first-line or second-line treatment in intention-to-treat and per protocol analysis. Pylera® as first- or second-line: Bismuth subcitrate potassium 140 mg, metronidazole 125 mg, and tetracycline 125 mg; 3 capsules four times daily for 10 days; and esomeprazole 20 mg bid for 10 days. Standard treatment as first line: Esomeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1,000 mg each bid for 14 days. Sequential as first line: Esomeprazole 20 mg bid for 10 days, amoxicillin 1,000 mg bid for 5 days, then clarithromycin 500 mg and tinidazole 500 mg bid for 5 days. Levofloxacin as second line: Levofloxacin 500 mg once daily, doxycycline 100 mg twice daily, and esomeprazole 20 mg twice daily for 10 days

Click here to view
Figure 4: Pooled mean intention-to-treat eradication rates of Helicobacter pylori shown in this graph as first-line treatments from the meta-analyses published between 2011 and 2021. PBMT = PPI, bismuth, metronidazole, and tetracycline, SEQ with quinolone = sequential therapy containing quinolone, STD sequential therapy = standard sequential therapy, Metro Clr, PPI = metronidazole, Clarithromycin, and PPI

Click here to view
Table 6: Comparison of first-line treatment recommendations of Helicobacter pylori from international guidelines

Click here to view


What are the treatment options when standard therapy fails?

Bismuth-based quadruple therapy, including Pylera®, for 10–14 days is recommended for patients who had failed to respond to standard therapy. Evidence to recommend or suggest a regimen as a second-line treatment is limited from Saudi Arabia because of the lack of sufficient clinical trials. Clarithromycin, metronidazole, amoxicillin, and levofloxacin resistance rates are high in Saudi Arabia. In one clinical trial from Saudi Arabia, eradication rate from a treatment regimen containing levofloxacin, doxycycline, and PPI was found to be substantially low.[118] In Egypt, in a randomized controlled trial using sequential therapy as a second-line treatment, the eradication rate was 74.6%.[128] Another trial carried out in Egypt with nitazoxanide, levofloxacin, doxycycline, and omeprazole for 14 days yielded 83% eradication on ITT analysis as second-line treatment.[129] [Table 7] shows different second-line treatment regimens from various guidelines and suitable treatment options for patients from Saudi Arabia.
Table 7: Second-line treatment regimens for the eradication of Helicobacter pylori after clarithromycin-triple therapy fails in first line

Click here to view


What are the treatment options when bismuth-based therapy fails?

Treatment regimens that have shown high eradication rates for the second-line treatments include bismuth-based quadruple therapy with probiotics, extending bismuth-based quadruple therapy to 14 days, levofloxacin–bismuth-containing quadruple therapy, vonoprazan-containing triple therapy, and combination of bismuth, clarithromycin, and tetracycline and high-dose dual therapy. The mean pooled eradication rates of the above-mentioned treatment range from 83% to 91%; however, no data are available from Saudi Arabia for these regimens.[127],[130],[131],[132],[133],[134],[135],[136] In geographical areas where high resistance to clarithromycin and levofloxacin (or other macrolides or quinolones) are reported, clarithromycin and levofloxacin (or another quinolone) containing treatment should not be repeated to treat refractory cases.

What are the treatment options when second-line treatment regimens fail?

Many international guidelines recommend endoscopy to perform culture with susceptibility testing or molecular determination of genotype resistance when second-line treatment fails.[37],[50],[137] The treatment options for this group of patients are extending the duration of bismuth-based quadruple therapy to 14 days, high-dose dual therapy, or combination of bismuth, levofloxacin, and tetracycline or metronidazole. The data to support these treatment regimens are not available from Saudi Arabia [Figure 5], [Figure 6], [Figure 7].
Figure 5: Helicobacter pylori eradication rates from clinical trials from the Arab World*. *Clinical trials testing the efficacy of Pylera® as a first line treatment for H. pylori is available from Saudi Arabia, Kuwait, and Lebanon. Clinical trials testing the efficacy of sequential therapy as first-line treatment is available from Saudi Arabia and the UAE. Clinical trials testing the efficacy of standard triple therapy is available from Saudi Arabia, the UAE, and Kuwait. Levofloxacin-based regimen as a second-line treatment was conducted from Saudi Arabia. From Egypt, sequential therapy and nitazoxide-based regimens were tested as a second-line treatment.

Click here to view
Figure 6: Pooled mean eradication rates (intention-to-treat analysis) of Helicobacter pylori from second-line treatment from the different meta-analyses published between 2011 and 2021. HDDT = high-dose dual therapy, PBMT = PPI, bismuth, metronidazole, and tetracycline, STD = standard triple therapy containing amoxicillin, clarithromycin, and PPI, Pylera® = bismuth, metronidazole, and tetracycline and PPI for 10 days

Click here to view
Figure 7: Suggested algorithm for management of Helicobacter pylori in Saudi Arabia

Click here to view


Treatment of patients with a true penicillin allergy

Bismuth-based quadruple therapy should be the first- and second-line treatment for patients with true penicillin allergy. Standard triple therapy with metronidazole and clarithromycin might be a choice if bismuth-based quadruple therapy is not available and only in areas where this regimen has proven efficacy.[37]

Role of probiotics in the management of H. pylori

Probiotics have recently been added to the antibiotics regimen to improve the eradication rate. The most used probiotic bacteria are Lactobacillus and Bifidobacterium. Recent data have shown an additional benefit of probiotics against H. pylori activity. Several studies have been conducted with favorable effects of different probiotics against H. pylori.[138],[139],[140],[141],[142],[143],[144] The possible mechanism of action of probiotics against H. pylori includes inhibiting the H. pylori growth by secreting short chain fatty acids that have antibacterial effect. It improves the strength of the mucosal barrier and has immunomodulatory mechanisms resulting in a reduction of gastric activity and inflammation.[145],[146],[147] It was also found that H. pylori infection is characterized by the release of various inflammatory mediators, such as chemokines and cytokines. Probiotics could modify the immunologic response by the modulation of anti-inflammatory cytokines secretion.

Several studies that assessed adding probiotic supplementation to H. pylori treatment showed positive results with improvement of H. pylori eradication rates and reduced side effects during therapy.[145],[148],[149] Lactobacillus species in particular have shown a stronger antibacterial activity against H. pylori in addition to Bifidobacterium strains and Saccharomyces boulardii.[140],[150],[151] Published data suggested that combining probiotics with a 14-day course of treatment by triple therapy did not improve the eradication of H. pylori infection compared to the placebo. However, probiotics did improve the adverse effects (AEs) of diarrhea and nausea.[136],[150] Other meta-analyses showed positive results and concluded that probiotics supplementation can improve the eradication rate of H. pylori compared to the therapy alone.[140],[144],[152],[153] Nevertheless, randomized, placebo-controlled trials evaluated the effect of probiotics as an adjuvant to standard triple therapy for eradication of H. pylori infection in children and showed conflicting results.[154],[155] Based on the current evidence, probiotics could not be recommended to be used in daily routine practice as an eradication regimen. However, its use as an adjunct therapy could improve the eradication rates and decrease treatment-related side effects.

Adherence to treatment regimen

H. pylori eradication can only be achieved if patients are adherent to the treatment regimen. Therefore, it is of utmost importance to educate patients regarding the adherence to treatment course and timing (PPI to be taken before meals and antibiotics after meals). It is important to ensure that adherence to treatment regimens were appropriate and satisfactory, otherwise subsequent treatment options will not be successful. It has been estimated that 10% of patients prescribed H. pylori eradication therapy will fail to take even 60% of medications. In one study, eradication levels of 96% were observed for patients who took 60% or more of medications compared to 69% for those taking less than 60% of prescribed medications. There are many factors behind the poor rate of adherence to treatment, including side effect of medication, duration and complexity of treatment, patient information, and physician motivation. The motivated physician can provide information to the patient that will lead to his or her empowerment to play an active role in their treatment by complying with therapy.[156],[157],[158]





H. pylori Infection in pediatrics

H. pylori infection in pediatric patients is higher in developing countries with a prevalence of 3–10% compared to 0.5% in developed countries.[159] It was also found that the infection is usually acquired at a young age, and infection rates are similar in males and females. In developed countries, less than 10% of children younger than 12 years are infected; however, seropositivity increases with age.[160] Most children infected with H. pylori are asymptomatic. A recent meta-analysis reported no association between H. pylori infection and gastrointestinal symptoms in children.[161] The most common manifestation in children was antral gastritis; however, duodenal and gastric ulcers have been reported but are less common in children compared to adults.[162] The risk of gastric MALT lymphoma and adenocarcinoma is rare in the pediatric population.[163] Children differ from adults in different respects to H. pylori infection; therefore, the recommendations for adults may not apply in children.

In 2017, a joint European Society for Pediatric Gastroenterology Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition made the following recommendations for the management of H. pylori in children and adolescents[164]:

  1. Recommended against a “test and treat” strategy for H. pylori infection in children.
  2. Recommended against diagnostic testing for H. pylori infection in children with functional abdominal pain disorders.
  3. Recommended against diagnostic testing for H. pylori infection as part of the initial investigation in children with IDA.
  4. Suggested that noninvasive diagnostic testing for H. pylori infection may be considered when investigating causes of chronic ITP.
  5. If the strain is susceptible to clarithromycin, triple therapy with amoxicillin and clarithromycin for 14 days is the preferred choice.
  6. Sequential therapy should not be given if the strain is resistant to metronidazole or clarithromycinor if susceptibility testing is not available.
  7. The doses of PPI and antibiotics should be calculated based on the body weight.
  8. Younger children need a higher PPI dose per body weight compared to adolescents and adults to obtain sufficient acid suppression.
  9. For children younger than 8 years, bismuth quadruple therapy refers to bismuth, amoxicillin, and metronidazole. In children older than 8 years, bismuth quadruple therapy refers to bismuth, tetracycline, and metronidazole,
  10. Current evidence does not support the routine addition of either single or combination probiotics to eradication therapy to reduce side effects and/or improve eradication rates.
  11. When H. pylori treatment fails, rescue therapy should be individualized considering antibiotic susceptibility, the age of the child, and available antimicrobial options.


In 2020, a recent update for Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition recommended H. pylori eradication for children with the following conditions[165]:

  1. Gastric and/or duodenal ulcers.
  2. Histological evidence of chronic gastritis
  3. Gastric MALT lymphoma.
  4. Protein-losing gastro-enteropathy, if other etiologies for the gastrointestinal protein loss are not found.
  5. IDA, when recurrent or refractory to iron supplement therapy.
  6. Chronic ITP as the first line therapy.
  7. Chronic idiopathic urticaria.


Adverse Effects (AE) of H. pylori treatments

The H. pylori eradication regimens are widely available in daily clinical practice. Overall, they are considered to be safe with good tolerability.[37] AEs of the standard H. pylori treatment have been observed in about 20% of the patients, with the majority being mild. However, severe type of AEs that necessitate medication discontinuations can occur in about 3% of patients. Nevertheless, serious adverse reactions were rarely reported. The common adverse reactions are fatigue (12%), anorexia (10%), abdominal pain/discomfort (9%), and diarrhea (8%).[166],[167],[168]

Headache, skin rash, and dizziness have been reported in (1–3%) of the patients on levofloxacin.[169] AEs have been recorded as well with the rescue therapy. For instance, myalgia and taste perversion were significantly more frequent with rifabutin compared to placebo.[170] Severe neutropenia and anemia have been reported in (0.4%) of patients treated with rifabutin.[171] In recent studies, myelotoxicity was the most significant adverse event of rifabutin. This complication is rare and occurred when a higher dose was used for a prolonged duration.[172],[173] In a population-based study in Hong Kong, the use of clarithromycin was associated with an increased risk of myocardial infarction, arrhythmia, and cardiac mortality in the short term, but not with long-term cardiovascular risks.[174] All patients with chronic renal or hepatic diseases should have an adjustment for some of the antimicrobial doses [Table 8].
Table 8: Medications that need to be adjusted in chronic liver or renal diseases.[175],[176]

Click here to view


Protective role of H. pylori

There have been signals that the eradication of H. pylori has been associated with an increase in the incidence of allergic asthma and other allergy-mediated diseases.[177],[178] This might be a direct AE from the drugs used in eradication therapy, or by losing the inhibitory effect of H. pylori on inflammation induced by T helper response; however, no convincing molecular mechanism has been proposed to support this theory. The risk of causing selective pressure on the organism and accelerating new antibiotic resistant strains causing loss of the efficacy of these drugs for its future use if needed. Also, where do antibiotic stewardship programs stand when it comes to universal eradication of H. pylori from the population?[179],[180] These questions and more might be mitigated by targeting those who have developed complications from the infection or those at high risk of developing complications.[181],[182],[183],[184] In addition, the potential downside of repeated antibiotic exposure in those who are at increased risk of adverse events, such as the elderly who have failed repeated courses of antibiotics, should be addressed on an individual level. Both epidemiological and basic experimental studies suggested a protective role of H. pylori infection against inflammatory bowel disease. In a meta-analysis, pooled relative risk depended on both, the region and the subtype (more protection against Crohn's disease in the East Asian region). In a case–controlled study, the rate of H. pylori infection was significantly lower in patients with ulcerative colitis (UC) compared with the control group, suggesting a protective role of H. pylori against the occurrence of UC.[185],[186],[187]

Cost effectiveness of H. pylori eradication

Although eradication of H. pylori is cost effective in the prevention of gastric cancer on an individual level,[188] whether a nationwide program for H. pylori eradication should be adopted would depend on numerous factors, some of which would be H. pylori prevalence in the population, the virulence of the prevalent strain, the success and cost of therapy, the willingness to pay threshold, and other factors. In a cost-effective study from Japan, it was modeled that a population-based eradication for all would be cost effective.[189] The Taipei global consensus recommended that a “screen-and-treat” strategy would be most cost effective in young adults in regions with a high incidence of gastric cancer.[190] To the counter argument, in a long-term follow-up study (13 years) of a randomized trial with an economic impact analysis from Denmark, there was no effect in terms of quality of life, and the cost of screening was higher compared to no screening.[191] Another element that would influence whether the eradication of H. pylori would be cost effective is the cost and the efficacy of the therapy in a particular population. This would encompass a mixture of drug resistance, cost of medication and testing, the adherence rate to therapy, and other factors. In a study comparing the efficacy of two regimens for the eradication of H. pylori in Saudi Arabia, AlRuthia et al.[192] found that sequential therapy was more cost saving and more effective with 56.25% confidence level, in comparison to standard triple therapy.

Vaccination against H. pylori

A vaccine against H. pylori would be a very attractive strategy for prevention of its complications but has been hindered since the initial trials in 1992. This is related to numerous factors of which is its ability to immunomodulate and evade the immune response of the human body against it. Several antigens have been targeted in the development of a human vaccine against H. pylori some of which include urease, catalase, CagA, VacA, and others. In addition to the technical challenges associated with the development of a vaccine against H. pylori, there have been other factors related to the financing of the studies.[193]

Future direction

Further studies are required to know the exact incidence and prevalence of H. pylori in Saudi Arabia. In addition, H. pylori antimicrobial susceptibility testing to different antibiotics using culture or non-culture test with a new generation PCR and DNA extraction technology is recommended. Randomized clinical trials are needed to determine the most appropriate duration of many regimens, such as quadruple therapy (10-day vs. 14-day), and if higher dosages of PPI and antimicrobials, such as amoxicillin and metronidazole, will improve the eradication rate of H. pylori infection. The efficacy of other regimens to eradicate H. pylori in Saudi Arabia, such as concomitant therapy, hybrid therapy, high-dose dual therapy, and bismuth-based quadruple therapy along with probiotics, vonoprazan-based triple therapy, and rifabutin-based therapy are unknown, and further clinical trials are needed. Therapies for treating patients who failed multiple treatment regimens are necessary. Finally, the working group recommends reviewing and updating this consensus report within 5–10 years.

Acknowledgements

The authors thank Rhea Laguerta for her support in writing the manuscript.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Malaty HM, Engstrand L, Pedersen NL, Graham DY. Helicobacter pylori infection: Genetic and environmental influences. A study of twins. Ann Intern Med 1994;120:982-6.  Back to cited text no. 1
    
2.
Testerman TL, Morris J. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol 2014;20:12781-808.  Back to cited text no. 2
    
3.
Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust 2016;204:376-80.  Back to cited text no. 3
    
4.
Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017;153:420-9.  Back to cited text no. 4
    
5.
al-Moagel MA, Evans DG, Abdulghani ME, Adam E, Evans DJ Jr, Malaty HM, et al. Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia, and comparison of those with and without upper gastrointestinal symptoms. Am J Gastroenterol 1990;85:944-8.  Back to cited text no. 5
    
6.
Almadi MA, Aljebreen AM, Tounesi FA, Abdo AA. Helicobacter pylori prevalence among medical students in a high endemic area. Saudi Med J 2007;28:896-8.  Back to cited text no. 6
    
7.
Telmesani AM. Helicobacter pylori: Prevalence and relationship with abdominal pain in school children in Makkah City, western Saudi Arabia. Saudi J Gastroenterol 2009;15:100-3.  Back to cited text no. 7
[PUBMED]  [Full text]  
8.
Hanafi MI, Mohamed AM. Helicobacter pylori infection: Seroprevalence and predictors among healthy individuals in Al Madinah, Saudi Arabia. J Egypt Public Health Assoc 2013;88:40-5.  Back to cited text no. 8
    
9.
Akeel M, Elmakki E, Shehata A, Elhafey A, Aboshouk T, Ageely H, et al. Prevalence and factors associated with H. pylori infection in Saudi patients with dyspepsia. Electron Physician 2018;10:7279-86.  Back to cited text no. 9
    
10.
Alharbi RH, Ghoraba M. Prevalence and patient characteristics of Helicobacter pylori among adult in primary health care of security forces hospital Riyadh, Saudi Arabia, 2018. J Family Med Prim Care 2019;8:2202-6.  Back to cited text no. 10
[PUBMED]  [Full text]  
11.
Weyermann M, Rothenbacher D, Brenner H. Acquisition of Helicobacter pylori infection in early childhood: Independent contributions of infected mothers, fathers, and siblings. Am J Gastroenterol 2009;104:182-9.  Back to cited text no. 11
    
12.
Dore MP, Bilotta M, Vaira D, Manca A, Massarelli G, Leandro G, et al. High prevalence of Helicobacter pylori infection in shepherds. Dig Dis Sci 1999;44:1161-4.  Back to cited text no. 12
    
13.
Kayali S, Manfredi M, Gaiani F, Bianchi L, Bizzarri B, Leandro G, et al. Helicobacter pylori, transmission routes and recurrence of infection: State of the art. Acta Biomed 2018;89:72-6.  Back to cited text no. 13
    
14.
Bellack NR, Koehoorn MW, MacNab YC, Morshed MG. A conceptual model of water's role as a reservoir in Helicobacter pylori transmission: Areview of the evidence. Epidemiol Infect 2006;134:439-49.  Back to cited text no. 14
    
15.
Alagl AS, Abdelsalam M, El Tantawi M, Madi M, Aljindan R, Alsayyah A, et al. Association between Helicobacter pylori gastritis and dental diseases: A cross-sectional, hospital-based study in Eastern Saudi Arabia. J Periodontol 2019;90:375-80.  Back to cited text no. 15
    
16.
Choi YK, Ahn JY, Won SH, Jung K, Na HK, Jung KW, et al. Eradication rate of Helicobacter pylori reinfection in Korea: A retrospective study. J Gastroenterol Hepatol 2019;34:1696-702.  Back to cited text no. 16
    
17.
Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, et al. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: Alarge-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect 2020;9:548-57.  Back to cited text no. 17
    
18.
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: Aworldwide incidence analysis. Lancet Glob Health 2020;8:e180-90.  Back to cited text no. 18
    
19.
Gong EJ, Ahn JY, Jung HY, Park H, Ko YB, Na HK, et al. Helicobacter pylori eradication therapy is effective as the initial treatment for patients with H. pylori-Negative and disseminated gastric mucosa-associated lymphoid tissue lymphoma. Gut Liver 2016;10:706-13.  Back to cited text no. 19
    
20.
Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology 2016;150:1113-24.e15.  Back to cited text no. 20
    
21.
Samuel R, Bilal M, Tayyem O, Guturu P. Evaluation and management of Non-variceal upper gastrointestinal bleeding. Dis Mon 2018;64:333-43.  Back to cited text no. 21
    
22.
Tsay FW, Hsu PI. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci 2018;25:65.  Back to cited text no. 22
    
23.
Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: Asystematic review and meta-analysis. Helicobacter 2008;13:323-40.  Back to cited text no. 23
    
24.
Kim BJ, Kim HS, Jang HJ, Kim JH. Helicobacter pylori eradication in idiopathic thrombocytopenic purpura: A meta-analysis of randomized trials. Gastroenterol Res Pract 2018;2018:6090878.  Back to cited text no. 24
    
25.
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019;3:3829-66.  Back to cited text no. 25
    
26.
Rizwan M, Fatima N, Alvi A. Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: Scenario from Saudi Arabia. Saudi J Gastroenterol 2014;20:212-8.  Back to cited text no. 26
[PUBMED]  [Full text]  
27.
Ashton-Key M, Diss TC, Isaacson PG. Detection of Helicobacter pylori in gastric biopsy and resection specimens. J Clin Pathol 1996;49:107-11.  Back to cited text no. 27
    
28.
Grove DI, Koutsouridis G, Cummins AG. Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. Pathology 1998;30:183-7.  Back to cited text no. 28
    
29.
Loffeld RJ, Stobberingh E, Flendrig JA, Arends JW. Helicobacter pylori in gastric biopsy specimens. Comparison of culture, modified giemsa stain, and immunohistochemistry. A retrospective study. J Pathol 1991;165:69-73.  Back to cited text no. 29
    
30.
Patel SK, Pratap CB, Jain AK, Gulati AK, Nath G. Diagnosis of Helicobacter pylori: What should be the gold standard? World J Gastroenterol 2014;20:12847-59.  Back to cited text no. 30
    
31.
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.  Back to cited text no. 31
    
32.
Fox JG, Yan L, Shames B, Campbell J, Murphy JC, Li X. Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus. Infect Immun 1996;64:3673-81.  Back to cited text no. 32
    
33.
Ng VL, Hadley WK, Fennell CL, Flores BM, Stamm WE. Successive bacteremias with “Campylobacter cinaedi” and “Campylobacter fennelliae” in a bisexual male. J Clin Microbiol 1987;25:2008-9.  Back to cited text no. 33
    
34.
Grayson ML, Tee W, Dwyer B. Gastroenteritis associated with Campylobacter cinaedi. Med J Aust 1989;150:214-5.  Back to cited text no. 34
    
35.
Du MQ, Isaacson PG. Recent advances in our understanding of the biology and pathogenesis of gastric mucosa-associated lymphoid tissue (malt) lymphoma. Forum (Genova) 1998;8:162-73.  Back to cited text no. 35
    
36.
Han SW, Flamm R, Hachem CY, Kim HY, Clarridge JE, Evans DG, et al. Transport and storage of Helicobacter pylori from gastric mucosal biopsies and clinical isolates. Eur J Clin Microbiol Infect Dis 1995;14:349-52.  Back to cited text no. 36
    
37.
Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212-39.  Back to cited text no. 37
    
38.
Wundisch T, Dieckhoff P, Greene B, Thiede C, Wilhelm C, Stolte M, et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology 2012;143:936-42; quiz e913-34.  Back to cited text no. 38
    
39.
Ferreri AJ, Govi S, Ponzoni M. The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. Curr Opin Oncol 2013;25:470-9.  Back to cited text no. 39
    
40.
Yang YX, Brill J, Krishnan P, Leontiadis G, American gastroenterological association clinical practice guidelines C. American gastroenterological association institute guideline on the role of upper gastrointestinal biopsy to evaluate dyspepsia in the adult patient in the absence of visible mucosal lesions. Gastroenterology 2015;149:1082-7.  Back to cited text no. 40
    
41.
Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002;16:779-86.  Back to cited text no. 41
    
42.
Lanza FL, Chan FK, Quigley EM, Practice parameters committee of the American College of G. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38.  Back to cited text no. 42
    
43.
Yuan W, Li Yumin, Yang Kehu, Ma Bin, Guan Quanlin, Wang D, et al. Iron deficiency anemia in Helicobacter pylori infection: Meta-analysis of randomized controlled trials. Scand J Gastroenterol 2010;45:665-76.  Back to cited text no. 43
    
44.
Jackson S, Beck PL, Pineo GF, Poon MC. Helicobacter pylori eradication: Novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol 2005;78:142-50.  Back to cited text no. 44
    
45.
Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter 2019;24:e12597.  Back to cited text no. 45
    
46.
Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, et al. Chinese Consensus Report on Family-based Helicobacter pylori Infection control and management (2021 Edition). Gut 2022;71:238-53.  Back to cited text no. 46
    
47.
El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, et al. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol 2018;16:992-1002.e6.  Back to cited text no. 47
    
48.
Kawanishi M. Development of reflux esophagitis following Helicobacter pylori eradication. J Gastroenterol 2005;40:1024-8.  Back to cited text no. 48
    
49.
Ishiki K, Mizuno M, Take S, Nagahara Y, Yoshida T, Yamamoto K, et al. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease. Clin Gastroenterol Hepatol 2004;2:474-9.  Back to cited text no. 49
    
50.
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30.  Back to cited text no. 50
    
51.
Leal YA, Flores LL, Garcia-Cortes LB, Cedillo-Rivera R, Torres J. Antibody-based detection tests for the diagnosis of Helicobacter pylori infection in children: Ameta-analysis. PLoS One 2008;3:e3751.  Back to cited text no. 51
    
52.
Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91:1138-44.  Back to cited text no. 52
    
53.
Savarino V, Vigneri S, Celle G. The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut1999;45(Suppl 1):18-22.  Back to cited text no. 53
    
54.
Ferwana M, Abdulmajeed I, Alhajiahmed A, Madani W, Firwana B, Hasan R, et al. Accuracy of urea breath test in Helicobacter pylori infection: Meta-analysis. World J Gastroenterol 2015;21:1305-14.  Back to cited text no. 54
    
55.
McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.  Back to cited text no. 55
    
56.
Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection -- Acritical review. Aliment Pharmacol Ther 2004;20:1001-17.  Back to cited text no. 56
    
57.
Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: Asystematic review and meta-analysis. Am J Gastroenterol 2006;101:1921-30.  Back to cited text no. 57
    
58.
Roy AD, Deuri S, Dutta UC. The diagnostic accuracy of rapid urease biopsy test compared to histopathology in implementing “test and treat” policy for Helicobacter pylori. Int J Appl Basic Med Res 2016;6:18-22.  Back to cited text no. 58
    
59.
Midolo P, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Urease tests. Gastroenterol Clin North Am 2000;29:871-8.  Back to cited text no. 59
    
60.
Montgomery EA, Martin DF, Peura DA. Rapid diagnosis of Campylobacter pylori by Gram's stain. Am J Clin Pathol 1988;90:606-9.  Back to cited text no. 60
    
61.
Zaitoun AM. Use of Romanowsky type (Diff-3) stain for detecting Helicobacter pylori in smears and tissue sections. J Clin Pathol 1992;45:448-9.  Back to cited text no. 61
    
62.
el-Zimaity HM. Accurate diagnosis of Helicobacter pylori with biopsy. Gastroenterol Clin North Am 2000;29:863-9.  Back to cited text no. 62
    
63.
Toulaymat M, Marconi S, Garb J, Otis C, Nash S. Endoscopic biopsy pathology of Helicobacter pylori gastritis. Comparison of bacterial detection by immunohistochemistry and Genta stain. Arch Pathol Lab Med 1999;123:778-81.  Back to cited text no. 63
    
64.
Anim JT, Al-Sobkie N, Prasad A, John B, Sharma PN, Al-Hamar I. Assessment of different methods for staining Helicobacter pylori in endoscopic gastric biopsies. Acta Histochem 2000;102:129-37.  Back to cited text no. 64
    
65.
Hsu WH, Wang SS, Kuo CH, Chen CY, Chang CW, Hu HM, et al. Dual specimens increase the diagnostic accuracy and reduce the reaction duration of rapid urease test. World J Gastroenterol 2010;16:2926-30.  Back to cited text no. 65
    
66.
Lan HC, Chen TS, Li AF, Chang FY, Lin HC. Additional corpus biopsy enhances the detection of Helicobacter pylori infection in a background of gastritis with atrophy. BMC Gastroenterol 2012;12:182.  Back to cited text no. 66
    
67.
van IMC, Laheij RJ, de Boer WA, Jansen JB. The importance of corpus biopsies for the determination of Helicobacter pylori infection. Neth J Med 2005;63:141-5.  Back to cited text no. 67
    
68.
El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: Role of the Sydney system. Hum Pathol 1999;30:72-7.  Back to cited text no. 68
    
69.
Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013;11:507-10.  Back to cited text no. 69
    
70.
Savarino V, Zentilin P, Pivari M, Bisso G, RaffaellaMele M, Bilardi C, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000;14:893-900.  Back to cited text no. 70
    
71.
Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322.  Back to cited text no. 71
    
72.
Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications. Lancet Infect Dis 2006;6:699-709.  Back to cited text no. 72
    
73.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018;155:1372-82.e17.  Back to cited text no. 73
    
74.
Alsohaibani F, Al Ashgar H, Al Kahtani K, Kagevi I, Peedikayil M, Alfadda A, et al. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol 2015;21:220-5.  Back to cited text no. 74
[PUBMED]  [Full text]  
75.
Valdivieso-Garcia A, Imgrund R, Deckert A, Varughese BM, Harris K, Bunimov N, et al. Cost analysis and antimicrobial susceptibility testing comparing the E test and the agar dilution method in Campylobacter jejuni and Campylobacter coli. Diagn Microbiol Infect Dis 2009;65:168-74.  Back to cited text no. 75
    
76.
Chisholm SA, Owen RJ. Application of polymerase chain reaction-based assays for rapid identification and antibiotic resistance screening of Helicobacter pylori in gastric biopsies. Diagn Microbiol Infect Dis 2008;61:67-71.  Back to cited text no. 76
    
77.
Vaira D, Vakil N, Menegatti M, van't Hoff B, Ricci C, Gatta L, et al. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002;136:280-7.  Back to cited text no. 77
    
78.
Chey WD, Metz DC, Shaw S, Kearney D, Montague J, Murthy U. Appropriate timing of the 14C-urea breath test to establish eradication of Helicobacter pylori infection. Am J Gastroenterol 2000;95:1171-4.  Back to cited text no. 78
    
79.
Neil GA, Suchower LJ, Ronca PD, Skoglund ML. Time of Helicobacter pylori eradication assessment following treatment. Helicobacter 1997;2:13-20.  Back to cited text no. 79
    
80.
Gatta L, Ricci C, Tampieri A, Osborn J, Perna F, Bernabucci V, et al. Accuracy of breath tests using low doses of 13C-urea to diagnose Helicobacter pylori infection: Arandomised controlled trial. Gut 2006;55:457-62.  Back to cited text no. 80
    
81.
Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: Asystematic review. Helicobacter 2004;9:347-68.  Back to cited text no. 81
    
82.
Nishikawa K, Sugiyama T, Kato M, Ishizuka J, Kagaya H, Hokari K, et al. A prospective evaluation of new rapid urease tests before and after eradication treatment of Helicobacter pylori, in comparison with histology, culture and 13C-urea breath test. Gastrointest Endosc 2000;51:164-8.  Back to cited text no. 82
    
83.
Eed EM, Hawash YA, Khalifa AS, Alsharif KF, Alghamdi SA, Saber T, et al. Molecular diagnosis of Helicobacter pylori antibiotic resistance in the Taif region, Saudi Arabia. Microbiol Immunol 2019;63:199-205.  Back to cited text no. 83
    
84.
Momenah A, Asghar A. Prevalence and antibiotic resistance among Helicobacter pylori clinical isolates from main Hospitals in the Western Region of Saudi Arabia. Pak J Med Sci 2008;24:100-3.  Back to cited text no. 84
    
85.
Eltahawy AT. Prevalence of primary Helicobacter pylori resistance to several antimicrobials in a Saudi Teaching Hospital. Med Princ Pract 2002;11:65-8.  Back to cited text no. 85
    
86.
Sezgin O, Aydin MK, Ozdemir AA, Kanik AE. Standard triple therapy in Helicobacter pylori eradication in Turkey: Systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol 2019;30:420-35.  Back to cited text no. 86
    
87.
Zhang G, Zou J, Liu F, Bao Z, Dong F, Huang Y, et al. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: Asystematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res 2013;46:607-13.  Back to cited text no. 87
    
88.
Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013;88:33-45.  Back to cited text no. 88
    
89.
Lee SW, Kim HJ, Kim JG. Treatment of Helicobacter pylori Infection in Korea: A systematic review and meta-analysis. J Korean Med Sci 2015;30:1001-9.  Back to cited text no. 89
    
90.
Kim JS, Ji JS, Choi H, Kim JH. Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: Systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2014;38:118-25.  Back to cited text no. 90
    
91.
Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A meta-analysis. Pharmacotherapy 2015;35:719-30.  Back to cited text no. 91
    
92.
Gong EJ, Yun SC, Jung HY, Lim H, Choi KS, Ahn JY, et al. Meta-analysis of first-line triple therapy for Helicobacter pylori eradication in Korea: Is it time to change? J Korean Med Sci 2014;29:704-13.  Back to cited text no. 92
    
93.
Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010;105:65-73.  Back to cited text no. 93
    
94.
Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis. Scand J Gastroenterol 2014;49:528-38.  Back to cited text no. 94
    
95.
Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661.  Back to cited text no. 95
    
96.
Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, et al. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: Asystematic review and network meta-analysis. Gut 2018;67:20-7.  Back to cited text no. 96
    
97.
Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, et al. The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta-analysis. Helicobacter 2020;25:e12714.  Back to cited text no. 97
    
98.
Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: Systematic review and network meta-analysis. BMJ 2015;351:h4052.  Back to cited text no. 98
    
99.
Puig I, Baylina M, Sanchez-Delgado J, López-Gongora S, Suarez D, García-Iglesias P, et al. Systematic review and meta-analysis: Triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother 2016;71:2740-53.  Back to cited text no. 99
    
100.
Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, et al. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J 2021;9:38-46.  Back to cited text no. 100
    
101.
Alsohaibani F, Alquaiz M, Alkahtani K, Alashgar H, Peedikayil M, AlFadda A, et al. Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia. Saudi J Gastroenterol 2020;26:84-8.  Back to cited text no. 101
[PUBMED]  [Full text]  
102.
Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter 2019;24:e12565.  Back to cited text no. 102
    
103.
Mestrovic A, Perkovic N, Bozic J, PavicicIvelja M, Vukovic J, Kardum G, et al. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLoS One 2020;15:e0244500.  Back to cited text no. 103
    
104.
Xu H, Wang W, Ma X, Feng R, Su Y, Cheng L, et al. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: Anetwork meta-analysis. Eur J Gastroenterol Hepatol 2021;33:775-86.  Back to cited text no. 104
    
105.
Losurdo G, Leandro G, Principi M, Giorgio F, Montenegro L, Sorrentino C, et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: The meta-analysis may be influenced by 'geographical weighting'. Int J Clin Pract 2015;69:1112-20.  Back to cited text no. 105
    
106.
Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, et al. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2016;43:470-81.  Back to cited text no. 106
    
107.
Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, Fallone CA, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016;2016:CD009034.  Back to cited text no. 107
    
108.
Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-Ge L, et al. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: An updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13.  Back to cited text no. 108
    
109.
Munteanu D, Etzion O, Ben-Yakov G, Halperin D, Eidelman L, Schwartz D, et al. Efficacy and safety of sequential versus quadruple therapy as second-line treatment for Helicobacter pylori infection-A randomized controlled trial. PLoS One 2017;12:e0183302.  Back to cited text no. 109
    
110.
Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter 2017;22.doi: 10.1111/hel. 12389.  Back to cited text no. 110
    
111.
Yurenev GL, Partzvania-Vinogradova EV, Andreev DN, Dicheva DT, Maiev IV. Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Ter Arkh 2018;90:33-9.  Back to cited text no. 111
    
112.
Song ZQ, Zhou LY. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol 2016;22:4766-75.  Back to cited text no. 112
    
113.
Chen KY, Lin TJ, Lin CL, Lee HC, Wang CK, Wu DC. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. World J Gastroenterol 2015;21:10435-42.  Back to cited text no. 113
    
114.
Zhang Y, Zhu YJ, Zhao Z, Zhao JT, Wang TY, Yang J, et al. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: An open-label, randomized trial. Eur J Gastroenterol Hepatol 2020;32:563-8.  Back to cited text no. 114
    
115.
Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter 2020;25:e12692.  Back to cited text no. 115
    
116.
Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, et al. Systematic review with meta-analysis: The efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 2016;44:427-37.  Back to cited text no. 116
    
117.
Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: Meta-analysis of randomized controlled trials. PLoS One 2014;9:e85620.  Back to cited text no. 117
    
118.
Alsohaibani FI, Alharfi SA, Almadi MA. Efficacy of levofloxacin doxycycline based rescue therapy for Helicobacter pylori eradication: A prospective open-label trial in Saudi Arabia. J Health Spec 2017;5:155-61.  Back to cited text no. 118
  [Full text]  
119.
Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. World J Gastroenterol 2015;21:10234-41.  Back to cited text no. 119
    
120.
Nyssen OP, Vaira D, Saracino IM, Fiorini G, Caldas M, Bujanda L, et al. Experience with Rifabutin-containing therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). J Clin Med 2022;11:1658.  Back to cited text no. 120
    
121.
Gingold-Belfer R, Niv Y, Levi Z, Boltin D. Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1392-402.  Back to cited text no. 121
    
122.
Navarro-Jarabo JM, Fernandez N, Sousa FL, Cabrera E, Castro M, Ramírez LM, et al. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate Helicobacter pylori infection. BMC Gastroenterol 2007;7:31.  Back to cited text no. 122
    
123.
Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, et al. Pharmacological regimens for eradication of Helicobacter pylori: An overview of systematic reviews and network meta-analysis. BMC Gastroenterol 2016;16:80.  Back to cited text no. 123
    
124.
Saeed LH, Mayet AY. Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci 2013;10:1497-502.  Back to cited text no. 124
    
125.
Lyu QJ, Pu QH, Zhong XF, Zhang J. Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. Biomed Res Int 2019;2019:9781212.  Back to cited text no. 125
    
126.
Ozaki H, Harada S, Takeuchi T, Kawaguchi S, Takahashi Y, Kojima Y, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: A large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion 2018;97:212-8.  Back to cited text no. 126
    
127.
Shinozaki S, Kobayashi Y, Osawa H, Sakamoto H, Hayashi Y, Lefor AK, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: Systematic review and meta-analysis. Digestion 2021;102:319-25.  Back to cited text no. 127
    
128.
Abuhammour A, Dajani A, Nounou M, Zakaria M. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naive and retreat patients. Arab J Gastroenterol 2016;17:131-6.  Back to cited text no. 128
    
129.
Abd-Elsalam S, Kobtan A, El-Kalla F, Elkhalawany W, Nawasany SE, Saif SA, et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 2016;95:e3879.  Back to cited text no. 129
    
130.
Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: Expert review. Gastroenterology 2021;160:1831-41.  Back to cited text no. 130
    
131.
Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter 2019;24:e12570.  Back to cited text no. 131
    
132.
Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, et al. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: Asystemic review and network meta-analysis. BMJ Open Gastroenterol 2020;7:e000472.  Back to cited text no. 132
    
133.
Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, et al. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:59-67.  Back to cited text no. 133
    
134.
Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e14396.  Back to cited text no. 134
    
135.
Munoz N, Sanchez-Delgado J, Baylina M, Puig I, López-Góngora S, Suarez D, et al. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori. Helicobacter 2018;23:e12488.  Back to cited text no. 135
    
136.
Zhang M, Chen CY, Wang XT, Lyu B. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of Helicobacter pylori as the rescue therapy: Ameta analysis]. Zhonghua Nei Ke Za Zhi 2017;56:368-74.  Back to cited text no. 136
    
137.
Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G. Tailored therapy versus empiric chosen treatment for Helicobacter pylori eradication: A meta-analysis. Medicine (Baltimore) 2016;95:e2750.  Back to cited text no. 137
    
138.
Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: Asystematic review and meta-analysis. World J Gastroenterol 2015;21:4345-57.  Back to cited text no. 138
    
139.
Lionetti E, Indrio F, Pavone L, Borrelli G, Cavallo L, Francavilla R. Role of probiotics in pediatric patients with Helicobacter pylori infection: Acomprehensive review of the literature. Helicobacter 2010;15:79-87.  Back to cited text no. 139
    
140.
Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:25-32.  Back to cited text no. 140
    
141.
Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: Arandomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46:220-7.  Back to cited text no. 141
    
142.
Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, et al. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: Arandomized, double-blind, placebo-controlled trial. Sci Rep 2018;8:2964.  Back to cited text no. 142
    
143.
Srinarong C, Siramolpiwat S, Wongcha-um A, Mahachai V, Vilaichone RK. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Asian Pac J Cancer Prev 2014;15:9909-13.  Back to cited text no. 143
    
144.
Zhu R, Chen K, Zheng YY, Zhang HW, Wang JS, Xia YJ, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014;20:18013-21.  Back to cited text no. 144
    
145.
Aiba Y, Nakano Y, Koga Y, Takahashi K, Komatsu Y. A highly acid-resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against Helicobacter pylori, and inhibits gastrin-mediated acid production in mice. Microbiologyopen 2015;4:465-74.  Back to cited text no. 145
    
146.
Gotteland M, Brunser O, Cruchet S. Systematic review: Are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23:1077-86.  Back to cited text no. 146
    
147.
Kim TS, Hur JW, Yu MA, Cheigh CI, Kim KN, Hwang JK, et al. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J Food Prot 2003;66:3-12.  Back to cited text no. 147
    
148.
Wiese M, Eljaszewicz A, Andryszczyk M, Gronek S, Gackowska L, Kubiszewska I, et al. Immunomodulatory effects of Lactobacillous plantarum and Helicobacter pylori CagA(+) on the expression of selected superficial molecules on monocyte and lymphocyte and the synthesis of cytokines in whole blood culture. J Physiol Pharmacol 2012;63:217-24.  Back to cited text no. 148
    
149.
Kim MN, Kim N, Lee SH, The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008;13:261-8.  Back to cited text no. 149
    
150.
Bhatia SJ, Kochar N, Abraham P, Nair NG, Mehta AP. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol 1989;27:2328-30.  Back to cited text no. 150
    
151.
Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 2004;70:518-26.  Back to cited text no. 151
    
152.
Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: Evidence from a meta-analysis. Rev Esp Enferm Dig 2013;105:445-53.  Back to cited text no. 152
    
153.
Lu M, Yu S, Deng J, Yan Q, Yang C, Xia G, et al. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: A meta-analysis of randomized controlled trials. PLoS One 2016;11:e0163743.  Back to cited text no. 153
    
154.
Li S, Huang XL, Sui JZ, hen SY, Xie YT, Deng Y, et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr 2014;173:153-61.  Back to cited text no. 154
    
155.
Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: Asystematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009;21:45-53.  Back to cited text no. 155
    
156.
Lee M, Kemp JA, Canning A, Egan C, Tataronis G, Farraye FA. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999;15:2312-6.  Back to cited text no. 156
    
157.
Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.  Back to cited text no. 157
    
158.
O'Connor JP, Taneike I, O'Morain C. Improving compliance with Helicobacter pylori eradication therapy: When and how? Therap Adv Gastroenterol 2009;2:273-9.  Back to cited text no. 158
    
159.
Kalach N, Bontems P, Raymond J. Helicobacter pylori infection in children. Helicobacter 2017;22(Suppl 1).doi: 10.1111/hel. 12414.  Back to cited text no. 159
    
160.
Kato S, Abukawa D, Furuyama N, Iinuma K. Helicobacter pylori reinfection rates in children after eradication therapy. J Pediatr Gastroenterol Nutr 1998;27:543-6.  Back to cited text no. 160
    
161.
Muhsen K, Jurban M, Goren S, Cohen D. Incidence, age of acquisition and risk factors of Helicobacter pylori infection among Israeli Arab infants. J Trop Pediatr 2012;58:208-13.  Back to cited text no. 161
    
162.
Spee LA, Madderom MB, Pijpers M, van Leeuwen Y, Berger MY. Association between Helicobacter pylori and gastrointestinal symptoms in children. Pediatrics 2010;125:e651-69.  Back to cited text no. 162
    
163.
Huang SC, Sheu BS, Lee SC, Yang HB, Yang YJ. Etiology and treatment of childhood peptic ulcer disease in Taiwan: Asingle center 9-year experience. J Formos Med Assoc 2010;109:75-81.  Back to cited text no. 163
    
164.
Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017;64:991-1003.  Back to cited text no. 164
    
165.
Kato S, Shimizu T, Toyoda S, Gold BD, Ida S, Ishige T, et al. The updated JSPGHAN guidelines for the management of Helicobacter pylori infection in childhood. Pediatr Int 2020;62:1315-31.  Back to cited text no. 165
    
166.
Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-79.  Back to cited text no. 166
    
167.
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.  Back to cited text no. 167
    
168.
Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014;5:392-9.  Back to cited text no. 168
    
169.
Gisbert JP, Morena F. Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.  Back to cited text no. 169
    
170.
Gisbert JP. Rifabutin for the treatment of Helicobacter pylori infection: A review. Pathogens 2020;10:15.  Back to cited text no. 170
    
171.
Apseloff G, Fluids G, LaBoy-Goral L, Kraut E, Vincent J. Severe neutropenia caused by recommended prophylactic doses of rifabutin. Lancet 1996;348:685.  Back to cited text no. 171
    
172.
Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-8.  Back to cited text no. 172
    
173.
Liu X, Wang H, Lv Z, Wang Y, Wang B, Xie Y, et al. Rescue therapy with a proton pump inhibitor plus amoxicillin and rifabutin for Helicobacter pylori infection: A systematic review and meta-analysis. Gastroenterol Res Pract 2015;2015:415648.  Back to cited text no. 173
    
174.
Wong AY, Root A, Douglas IJ, Chui CSL, Chan EW, Ghebremichael-Weldeselassie Y, et al. Cardiovascular outcomes associated with use of clarithromycin: Population based study. BMJ 2016;352:h6926.  Back to cited text no. 174
    
175.
Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg M, et al. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open 2016;6:e012991.  Back to cited text no. 175
    
176.
Aloy B, Launay-Vacher V, Bleibtreu A, Bortolotti P, Faure E, Filali A, et al. Antibiotics and chronic kidney disease: Dose adjustment update for infectious disease clinical practice. Med Mal Infect 2020;50:323-31.  Back to cited text no. 176
    
177.
Salama NR, Hartung ML, Muller A. Life in the human stomach: Persistence strategies of the bacterial pathogen Helicobacter pylori. Nat Rev Microbiol 2013;11:385-99.  Back to cited text no. 177
    
178.
Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: Perspectives and time trends. Nat Rev Gastroenterol Hepatol 2014;11:628-38.  Back to cited text no. 178
    
179.
Graham DY, Liou JM. Primer for development of Guidelines for Helicobacter pylori therapy using antimicrobial stewardship. Clin Gastroenterol Hepatol 2022;20:973-83. e971.  Back to cited text no. 179
    
180.
Leja M, Dumpis U. What would the screen-and-treat strategy for Helicobacter pylori mean in terms of antibiotic consumption? Dig Dis Sci 2020;65:1632-42.  Back to cited text no. 180
    
181.
Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology 2018;155:67-75.  Back to cited text no. 181
    
182.
Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med 2020;382:427-36.  Back to cited text no. 182
    
183.
Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA clinical practice update on the diagnosis and management of atrophic gastritis: Expert review. Gastroenterology 2021;161:1325-32.e27.  Back to cited text no. 183
    
184.
Wauters L, Dickman R, Drug V, Mulak A, Serra J, Enck P, et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United European Gastroenterol J 2021;9:307-31.  Back to cited text no. 184
    
185.
Yu Y, Zhu S, Li P, Min L, Zhang S. Helicobacter pylori infection and inflammatory bowel disease: Acrosstalk between upper and lower digestive tract. Cell Death Dis 2018;9:961.  Back to cited text no. 185
    
186.
Ali I, Abdo Q, Al-Hihi SM, Shawabkeh A. Association between ulcerative colitis and Helicobacter pylori infection: A case-control study. Heliyon 2022;8:e08930.  Back to cited text no. 186
    
187.
Imawana RA, Smith DR, Goodson ML. The relationship between inflammatory bowel disease and Helicobacter pylori across East Asian, European and Mediterranean countries: Ameta-analysis. Ann Gastroenterol 2020;33:485-94.  Back to cited text no. 187
    
188.
Han Y, Yan T, Ma H, Yao X, Lu C, Li Y, et al. Cost-effectiveness analysis of Helicobacter pylori eradication therapy for prevention of gastric cancer: A Markov model. Dig Dis Sci 2020;65:1679-88.  Back to cited text no. 188
    
189.
Kowada A, Asaka M. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis. Helicobacter 2021;26:e12837.  Back to cited text no. 189
    
190.
Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: The Taipei global consensus. Gut 2020;69:2093-112.  Back to cited text no. 190
    
191.
Hogh MB, Kronborg C, Hansen JM, Schaffalitzky de Muckadell OB. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther 2019;49:1013-25.  Back to cited text no. 191
    
192.
AlRuthia Y, Almadi MA, Alqahtani S, Alrasheed H, Al-Owairdhi M, Alsohaibani F. The cost-effectiveness of sequential versus standard triple therapy for Helicobacter pylori eradication in Saudi Arabia. Saudi J Gastroenterol 2021;27:217-22.  Back to cited text no. 192
[PUBMED]  [Full text]  
193.
Dos Santos Viana I, Cordeiro Santos ML, Santos Marques H, Lima de Souza Gonçalves V, Bittencourt de Brito B, França da Silva FA, et al. Vaccine development against Helicobacter pylori: From ideal antigens to the current landscape. Expert Rev Vaccines 2021;20:989-99.  Back to cited text no. 193
    

Top
Correspondence Address:
Fahad Alsohaibani,
Department of Medicine, King Faisal Specialist Hospital and Research Center, P.O Box 3354, Riyadh - 11211
Kingdom of Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/sjg.sjg_288_22



    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8]



 

Top
Previous Article   Next Article
 
  Search
 
  Ahead Of Print
  
     Search Pubmed for
 
    -  Alsohaibani F
    -  Peedikayil M
    -  Alshahrani A
    -  Somily A
    -  Alsulaiman R
    -  Azzam N
    -  Almadi M
        PDF Version


    Abstract
   Epidemiology
   Microbiology
   Diagnosis
   Diagnostic Methods
   Management
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed9719    
    PDF Downloaded36    

Recommend this journal